Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regentis BiomaterialsRGNT +7.21%14 Debt-to-EBITDA is -0.06 as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Regentis Biomaterials ranks worse than 213219.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Regentis Biomaterials's Debt-to-EBITDA or its related term are showing as below:
RGNT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.09 Med: -1.62 Max: 1
Current: -0.09
During the past 6 years, the highest Debt-to-EBITDA Ratio of Regentis Biomaterials was 1.00. The lowest was -9.09. And the median was -1.62.
RGNT's Debt-to-EBITDA is ranked worse than 100% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs RGNT: -0.09
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Regentis Biomaterials Debt-to-EBITDA Related Terms
Regentis Biomaterials Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Regentis Biomaterials's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGNT vs HBIO, MLSS, RVP: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regentis Biomaterials Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Regentis Biomaterials's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Regentis Biomaterials (RGNT) has a Debt-to-EBITDA of -0.06 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Regentis Biomaterials. According to the industry distribution chart, Regentis Biomaterials ranks #999999 out of 469 companies in the Medical Devices & Instruments industry.
Is Regentis Biomaterials' Debt-to-EBITDA too high?
Regentis Biomaterials' current Debt-to-EBITDA is -0.06. Based on the distribution chart, Regentis Biomaterials ranks #999999 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Debt-to-EBITDA compare to HBIO and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Regentis Biomaterials ranks #999999 out of 469 companies for Debt-to-EBITDA. This places Regentis Biomaterials in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Regentis Biomaterials. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regentis Biomaterials's current Debt-to-EBITDA is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Debt-to-EBITDA of -0.06. The current Debt-to-EBITDA is -0.06. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Debt-to-EBITDA is -0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score
Get the complete analysis for RGNT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGNT has been successfully added to your 
